^
    3d
    PIPSeN: Trial Evaluating Maintenance Olaparib in Patients With Platinum-sensitive Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=180, Terminated, Gustave Roussy, Cancer Campus, Grand Paris | N=600 --> 180 | Unknown status --> Terminated; study design, change of standard of care, enrollment difficulties
    Enrollment change • Trial termination • Platinum sensitive
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    ALK translocation
    |
    Lynparza (olaparib)
    7d
    Automated extraction of temporalized tumor evolution from oncology EMRs using natural language processing. (PubMed, ESMO Real World Data Digit Oncol)
    Reviewing automatically collected data was 5.8 times faster compared with manual collection. Our solution demonstrates robust performance for extracting temporally structured tumor outcomes from EMRs and supports the reconstruction of real-world endpoints in oncology.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase)
    |
    KRAS mutation • EGFR mutation • ALK translocation
    10d
    DIONE-01: A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers (clinicaltrials.gov)
    P1, N=210, Active, not recruiting, iOnctura | Trial completion date: Mar 2025 --> Mar 2027
    Trial completion date • First-in-human
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    BRAF mutation • BRAF V600 • ALK translocation
    |
    PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay
    |
    cisplatin • Bavencio (avelumab) • Jakafi (ruxolitinib) • pemetrexed • roginolisib (IOA-244)
    16d
    NIBIT-ML-1: A randomized, run-in, phase II study of nivolumab combined with ipilimumab and oral decitabine/cedazuridine (ASTX727) or nivolumab combined with ipilimumab in melanoma and NSCLC patients resistant to anti-PD-1/PD-L1 (2024-518891-29-00)
    P1/2, N=148, Recruiting, Fondazione NIBIT Onlus | Not yet recruiting --> Recruiting
    Enrollment open
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation • BRAF mutation • ALK translocation
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Inqovi (decitabine/cedazuridine)
    1m
    NIRVANA-LUNG: PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=327, Active, not recruiting, UNICANCER | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK positive • ALK translocation
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed
    2ms
    C5851005: A Study to Learn About the Study Medicine Called PF-08046054/SGNPDL1V Versus Docetaxel in Adult Participants with Previously-treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-small-cell Lung Cancer (NSCLC) (2025-521281-97-00)
    P2/3, N=246, Recruiting, Pfizer Inc.
    New P2/3 trial
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • EGFR mutation • ALK translocation
    |
    PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay
    |
    docetaxel • PF-08046054
    2ms
    IBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=10, Not yet recruiting, Innovent Biologics (Suzhou) Co. Ltd.
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • ALK translocation
    2ms
    ALK-positive ALCL: first described adult case of synchronous CNS and systemic involvement at presentation: a case report and review of the literature. (PubMed, Br J Neurosurg)
    The patient was treated with a modified MARIETTA protocol (without rituximab) and consolidated with a carmustine-based autologous stem cell transplant. shows complete metabolic response on PET-CT and MRI brain. This case presents the first successful treatment of a synchronous presentation of CNS and systemic ALK-positive ALCL, and the importance of a multidisciplinary approach for diagnosis.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • NPM1 (Nucleophosmin 1) • TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    ALK positive • ALK fusion • ALK translocation
    |
    Rituxan (rituximab) • carmustine
    2ms
    Pioneer study: a prospective, single arm, exploratory clinical study of anti-pd-1/ctla-4 combination antibody combined with bevacizumab in the treatment of non squamous non-small cell lung cancer after immune resistance (ChiCTR2500112841)
    P=N/A, N=36, Recruiting, The First Affiliated Hospital of Bengbu Medical University; The First Affiliated Hospital of Bengbu Medical University
    New trial
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK translocation
    |
    VENTANA PD-L1 (SP263) Assay
    |
    Avastin (bevacizumab) • Qibeian (iparomlimab/tuvonralimab)
    2ms
    Case Report: diffuse entire gastrointestinal tract involvement of ALK-positive anaplastic large cell lymphoma harboring JAK-STAT pathway mutations in an adolescent with leukemoid reaction. (PubMed, Front Oncol)
    In further studies, RNA sequencing confirmed the presence of NPM1::ALK gene fusion in this case; whole-exome sequencing (WES) detected somatic mutations in multiple genes of the JAK-STAT pathway (including JAK1, PTPN6, MTOR, and TYK2). It is noteworthy that such genetic alterations are more commonly observed in ALK-negative anaplastic large cell lymphoma (ALK-ALCL) but are less commonly reported in ALK+ALCL.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • NPM1 (Nucleophosmin 1) • TNFRSF8 (TNF Receptor Superfamily Member 8) • JAK1 (Janus Kinase 1) • TYK2 (Tyrosine Kinase 2)
    |
    ALK positive • ALK fusion • TNFRSF8 positive • TNFRSF8 expression • ALK translocation • ALK negative
    3ms
    Ladarixin With Sotorasib in Advanced NSCLC (clinicaltrials.gov)
    P1, N=40, Recruiting, NYU Langone Health | Trial completion date: Aug 2026 --> Aug 2027 | Trial primary completion date: Aug 2025 --> Aug 2027
    Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    KRAS mutation • KRAS G12C • ALK rearrangement • KRAS G12 • ALK translocation
    |
    Lumakras (sotorasib) • ladarixin (DF-2156A)
    4ms
    Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial) (clinicaltrials.gov)
    P3, N=166, Active, not recruiting, ECOG-ACRIN Cancer Research Group | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    ALK (Anaplastic lymphoma kinase) • EML4 (EMAP Like 4)
    |
    ALK positive • ALK fusion • ALK translocation
    |
    Xalkori (crizotinib)